DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions

Information source: Actavis Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: morphine sulfate sustained-release capsules (Drug); KADIAN (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Actavis Inc.

Official(s) and/or principal investigator(s):
Daniel V. Freeland, DO, Principal Investigator, Affiliation: CEDRA Clinical Research, LLC


The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x 100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered under fed conditions.

Clinical Details

Official title: A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Under Fed Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Mean Maximum Plasma Morphine Concentration

Secondary outcome:

Time of Maximum Plasma Morphine Concentration

Area Under the Curve to the Last Measurable Time Point for Plasma Morphine

Area Under the Curve to Infinity for Plasma Morphine


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Subject must be a male or non-pregnant, non-breast-feeding female.

- Subject must be between 18 and 50 years of age inclusive.

- Subject's body weight should be within +/- 15% of the ideal body weight for their

height and estimated frame based on the Metropolitan Life Insurance Company Table and weigh a minimum of 50 kg (110 lbs).

- Female subjects - not surgically sterile or at least two years postmenopausal - must

agree to utilize one of the following forms of contraception, if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal or injection), double barrier (condom and diaphragm with spermicide), IUD, or vasectomized partner (6 months minimum).

- Subject must voluntarily consent to participate in this study and provide their

written informed consent prior to completion of any study-specific procedures.

- Subject is willing and able to remain in the study unit for the entire duration of

each confinement period and return to the study site for any outpatient visits. Exclusion Criteria:

- History or presence of clinically significant cardiovascular, pulmonary, hepatic,

renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic or psychiatric disease or any other condition which, in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.

- Has a clinically significant abnormal finding on the physical exam, medical history

or clinical laboratory results at screening.

- History or presence of allergic or adverse response to the study drug or related


- Has been on a significantly abnormal diet during the four weeks preceding the first

dose of study medication.

- Has donated blood or plasma within 30 days prior to the first dose of study


- Has participated in another clinical trial within 30 days prior to first dose of

study medication.

- Has used any over-the-counter (OTC) medication including vitamins, within 7 days

prior to the first dose of study medication without evaluation and approval by the study investigator.

- Has used any prescription medication, except hormonal contraceptive or hormonal

replacement therapy, within 7 days prior to the first dose of study medication without evaluation and approval by the study investigator.

- Has been treated with any known enzyme altering drugs such as barbiturates,

phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.

- Has smoked or used tobacco products within 60 days prior to the first dose of study


- Has a history of substance abuse (including alcohol) in the past 5 years.

- Is a female with a positive pregnancy test result.

- Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,

benzodiazepines, cocaine, cannabinoids, opiates).

- Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.

Locations and Contacts

CEDRA Clinical Research, LLC, Austin, Texas 78759, United States
Additional Information

Starting date: August 2004
Last updated: August 13, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017